用于识别抗肿瘤新药A166的化学功能材料的开发

A166 is an ADC drug targeting HER2,mainly used for the treatment of HER2-positive breast cancer and other solid tumors expressing HER2.Clinical drug monitoring after administration is crucial for clinical medication guidance, as it can optimize the dosing regiments to enhance efficacy, minimize side effects, and reduce the development of drug resistance.Currently, the main methods for therapeutic drug monitoring(TDM) include immunoassay methods, chromatography methods(such as high-performance liquid chromatography HPLC),and emerging point-of-care technologies(such as mass spectrometry).However, these methods have several drawbacks, including the need for highly trained operators, high cost, equipment maintenance, and complex procedures.To address the challenge of monitoring A166 blood concentration, a novel strategy was proposed by combining boronic acid-modified rhodamine 6G-functionalized graphene oxide(HR6GGO) with a boronic acid-affinity molecularly imprinted magnetic nanoparticle(MIP-A166).The HR6GGO material, modified with borate and loaded with a large amount of rhodamine 6G fluorescent dye, can selectively label A166 through boronic acid affinity, achieving fluorescence signal amplification and output.HRBGO and MIP-A166 were successfully prepared and the MIP-A166-HRBGO strategy achieved extremely high sensitivity and excellent specificity for the detection of A166 after experimental optimization.MIP-A166 utilizes the boronic acid affinity molecular imprinting recognition mechanism, showing specific selectivity for the template drug.The sandwich detection strategy, based on the coupling of MIP-A166 with HR6GGO,relies the dual boronic acid affinity synergism, demonstrating board application potential and providing a promising tool for clinical drug monitoring and medication guidance.